Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy
Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy
复制标题
DOI：
10.1182/blood-2004-07-2717
复制
发表时间：
2005-02-01
期刊：
影响因子：
20.3
通讯作者：
Wagner, JE
中科院分区：
文献类型：
--
作者：
Barker, JN;Weisdorf, DJ;Wagner, JE
有限的脐带血（UCB）细胞剂量损害成人UCB移植的结果。因此，为了增加移植细胞剂量，我们评估了2个部分人类白细胞抗原（HLA）匹配的UCB单位联合移植的安全性。23例高危恶性血液病患者（中位年龄24岁;范围13-53岁）在清髓性预处理后接受了2个UCB单位（中位输注剂量3.5 x 10（7）有核细胞[NC]/ kg;范围1.1-6.3 x 10（7）NC/kg）。所有可评价患者（n = 21）均在中位23天（范围：15-41天）植入。在第21天，24%的患者植入来自两个供体，76%的患者植入来自单个供体，到第100天，所有患者中1个单位占主导地位。尽管有核或CD 34（+）细胞剂量和HLA匹配均不能预测哪个单位占优势，但占优势的单位具有显著较高的CD 3（+）剂量（P
Limited umbilical cord blood (UCB) cell dose compromises the outcome of adult UCB transplantation. Therefore, to augment graft cell dose, we evaluated the safety of the combined transplantation of 2 partially human leukocyte antigen (HLA)-matched UCB units. Twenty-three patients with high-risk hematologic malignancy (median age, 24 years; range, 13-53 years) received 2 UCB units (median infused dose, 3.5 x 10(7) nucleated cell [NC]/ kg; range, 1.1-6.3 x 10(7) NC/kg) after my-eloablative conditioning. All evaluable patients (n = 21) engrafted at a median of 23 days (range, 15-41 days). At day 21, engraftment was derived from both donors in 24% of patients and a single donor in 76% of patients, with 1 unit predominating in all patients by day 100. Although neither nucleated or CD34(+) cell doses nor HLA-match predicted which unit would predominate, the predominating unit had a significantly higher CD3(+) dose (P